Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Boltz raises $110M Series A for AI drug discovery

AI summary

London-based Boltz raised a $110 million Series A led by Bessemer Venture Partners, following a $28 million seed round in 2025. The company sells BoltzMol-1 and BoltzProt-1 through Boltz Lab and an API, offering molecular screening and protein design without operating its own drug pipeline. Boltz reported 50-fold growth in customer token consumption since June and said six of the 20 largest pharmaceutical companies were clients, though the supplied reports do not independently verify these usage and adoption figures.

In-depth insight

The financing gives Boltz additional capital to expand compute, hiring, and model development as it pursues a usage-based model for selling molecular-design AI to researchers and pharmaceutical companies.

Boltz PBC, a startup that develops artificial intelligence models for pharmaceutical researchers, has raised $110 million in funding.

Bessemer led the Series A investment. Boltz stated on Wednesday that the fund was joined by a large group of new and returning backers. The consortium included Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird and others.

Small molecules, the building blocks of many drugs, can only neutralize a pathogen after binding to it. As a result, researchers start drug discovery projects by looking for molecules that have a high binding affinity with pathogens. They often review hundreds of thousands of candidate molecules per project. The process can take months and often costs millions of dollars.

Boltz offers an AI model called BoltzMol-1 that speeds up the workflow. It generates binding affinity data by reviewing only a few dozen, particularly promising molecules instead of the hundreds of thousands usually needed. The fewer molecules need to be studied, the less time the analysis takes.

Binding affinity evaluations don’t yield drug discoveries right away. Instead, they produce data points called small molecule hits. Those are essentially faint clues that help researchers pinpoint the area where they should focus their efforts.

#Boltz#Bessemer Venture Partners#Andreessen Horowitz#BoltzMol-1#BoltzProt-1#Boltz Lab#Boltz API

Original · 3 min readRead the original
Group chat

No comments yet. Start the conversation.